AstraZeneca Signs Research Agreement With Shizuoka Prefecture Cancer Center
This article was originally published in PharmAsia News
Executive Summary
Osaka based AstraZeneca Japan signed an agreement Aug. 18 with the Shizuoka Prefecture Cancer Center to conduct basic research and clinical trials in an effort to develop new cancer drugs. According to the agreement, as the pharmaceutical company with the most cancer drugs in Japan, AstraZeneca will engage with center researchers starting from the drug candidate selection phase, and will use the feedback to speed up the developmental process of cancer drugs targeting Japanese and other Asian patients. It is the first such agreement between a global pharmaceutical company and a medical facility in Japan. (Click here for more - Japanese language) "The Shizuoka Prefecture Cancer Center Signs Development Agreement With Pharmaceutical Company" - Mainichi News (8/19/08)
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.